SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

March 9, 2018: By Joan McKenna

SightLifeSurgicalSightLife Surgical has acquired the KAMRA corneal inlay from AcuFocus, the two companies announced March 8.

Terms were not disclosed.

AcuFocus, in Irvine, California, said the move allows it to focus on commercializing its IC-8 small aperture intraocular lens in the US market.

AcuFocus KAMRA

AcuFocus KAMRA

SightLife Surgical, a Seattle-based subsidiary of the nonprofit SightLife, said the KAMRA fits into its mission to eliminate corneal blindness by 2040. SightLife Surgical provides corneal tissue and medical devices to surgeons for corneal transplants.

The KAMRA gained US approval in April 2015 for the surgical correction of presbyopia. The opaque mini-ring is designed to use the pinhole effect to extend depth of focus in presbyopic patients.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023